SLU-PP-332 dosing (preclinical regimens)
> Updated:
Calculate the SLU-PP-332 dose
The calculator is already set up for SLU-PP-332 — adjust the dose or diluent volume for your vial.
Human dosing
SLU-PP-332 has been administered subcutaneously in reported use (reconstituted 5 mg vial); the figures below are generalized from descriptive community protocols, as no human clinical trials exist (all published data are in mice).
SLU-PP-332 dosage is described very inconsistently across public sources, so the numbers below are consolidated into one reference range rather than another general description of the compound.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start | 250 mcg subcutaneously, once daily | Starting dose |
| Intermediate | 500 mcg – 1 mg subcutaneously, once daily | Increase if needed |
| Upper level | 1.5 mg subcutaneously, once daily | Maximum in this schedule |
Background on the molecule, its mechanism and primary sources is covered in the monograph.
Practical dosing and effect details
In Billon and colleagues' study (ACS Chemical Biology, 2023), SLU-PP-332 was given to mice intraperitoneally, and frequency, not a single dose, drove the outcome: daily administration activated a muscle transcriptional program resembling the one triggered by acute aerobic exercise and improved running endurance. The authors describe this effect as ERRα-dependent, meaning it traces to the ERRα receptor specifically rather than to a general action of the compound on muscle tissue. The data come from mice only.
The schedule on this page (250 mcg to start, up to 1.5 mg at the upper range, once daily) follows the same logic: in the study, the effect built up gradually over several days of regular daily dosing, not right after the first injection.
The 5 mg vial mentioned above is reconstituted specifically for daily doses of that size, so the packaging matches the schedule on this page.
This is reference information for planning a research protocol, not a medical recommendation and not instructions for self-administration.
How to reconstitute
An example reconstitution for convenient dosing. The exact ratios depend on your vial. For research reference only — not medical guidance.
- 1Add the diluentUse bacteriostatic water. Example: 2 ml into a 10 mg vial.SLU-PP-33210 mg+ 2 mlDiluent
- 2Get the concentrationExample: 10 mg in 2 ml =SLU-PP-3325 mg/ml(5,000 mcg/ml)
- 3Work out the volume per doseFor example, for a 0.25 mg dose:0.25 mg = 0.05 ml= 5 u. (U-100)
This is only an example calculation. You can use a different diluent volume — plug your own numbers into the calculator. Open calculator →
Research protocols
SLU-PP-332: reference regimens
Controlled data on this compound are limited.
More scientific background in the SLU-PP-332 monograph
Notes and safety
- • SLU-PP-332 is a research peptide. Human safety and efficacy data are limited.
- • The regimens shown are based on publications and research protocols, not clinical recommendations.
- • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
- • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
- • This information is for educational purposes and is not medical advice.
SLU-PP-332